{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'assent will be obtained based on those requirements. Each parent/caregiver and subject should be', 'given both verbal and written information describing the nature and duration of the clinical', 'study. The informed consent process should take place under conditions where the', 'parent/caregiver has adequate time to consider the risks and benefits associated with his/her', \"child's participation in the study. Subjects will not be screened or treated until the\", 'parent/caregiver and subject has signed an approved ICF and assent form written in a language in', 'which the subject is fluent. The ICF and assent forms that are used must be approved both by', 'BioCryst and by the reviewing IRB/IEC. The ICF and assent forms should be in accordance with', 'the current revision of the Declaration of Helsinki, current ICH and GCP guidelines, and', 'BioCryst policy.', 'The Investigator must explain to potential subjects and their parent/caregiver the aims, methods,', 'reasonably anticipated benefits, and potential hazards of the trial and any discomfort it may', 'entail. Each parent/caregiver will be informed that they are free for their child not to participate', 'in the trial and that they may withdraw consent for their child to participate at any time. They', 'will be told that refusal for their child to participate in the study will not prejudice future', \"treatment. They will also be told that their child's records may be examined by competent\", 'authorities and authorized persons but that personal information will be treated as strictly', 'confidential and will not be publicly available.', 'Parents/caregivers and subjects must be given the opportunity to ask questions. After this', 'explanation and before entry into the trial, consent and assent should be appropriately recorded', \"by means of the parent's/caregiver's dated signature. The parent/caregiver should receive a\", 'signed and dated copy of the ICF, and the assent. The original signed informed consent and', 'assent should be retained in the study files. The Investigator shall maintain a log of all subjects', 'for whom consent was signed and indicate if the subject was enrolled into the study or reason for', 'non-enrollment.', '14.1.5.', 'Investigator Reporting Requirements', 'The Investigator will provide timely reports regarding safety to his/her IRB/IEC as required.', '14.2.', 'Study Monitoring', 'During trial conduct, BioCryst or its designee will conduct periodic monitoring visits to ensure', 'that the protocol and GCPs are being followed. The monitors will review source documents to', 'confirm that the data recorded on CRFs are accurate. The Investigator and institution will allow', 'BioCryst representatives, monitors, or its designees direct access to source documents to perform', 'this verification.', 'It is important that the Principal Investigator(s) and their relevant personnel are available during', 'the monitoring visits and that sufficient time is devoted to the process.', '14.3.', 'Quality Assurance', 'The Principal Investigator may be subject to visits by the IRB/IEC, and/or by a quality assurance', 'group for audits performed by BioCryst, or its designee, and/or to inspection by appropriate', 'regulatory authorities.', '100']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'It is important that the Investigator(s) and their relevant personnel are available during the', 'possible audits or inspections and that sufficient time is devoted to the process.', '14.4.', 'Study Termination and Site Closure', 'Overall, the Sponsor may suspend enrollment into the study, suspend treatment of ongoing', \"subjects, or terminate the study to ensure that subjects' safety and welfare are protected. The\", 'entire study, or individual sites, may be terminated for any of the following reasons:', 'Changes in scientific knowledge that lead to a negative impact on the risk/benefit', 'profile for subjects', 'Request of BioCryst or competent public authorities/IRB/IEC', 'If recruitment cannot be completed in specified time frame', 'If the permit to manufacture or import IMP is revoked', 'If the study drug becomes commercially available or another mechanism is available', 'to provide drug to the subject', 'BioCryst reserves the right to discontinue the trial prior to inclusion of the intended number of', 'subjects but intends only to exercise this right for valid scientific or administrative reasons. After', 'such a decision, the Investigator must contact all participating subjects immediately after', 'notification. As directed by BioCryst, all study materials must be collected and all CRFs', 'completed to the greatest extent possible.', 'An individual trial center that is determined to be unsuitable by Sponsor, competent public', 'authorities or IRB/IEC may be terminated, without affecting the other trial sites.', 'Except for those situations outlined in Section 8.3, no other formal stopping rules for individual', 'subjects, parts of the trial or the entire trial, will be defined. Individual subjects will be', 'discontinued from the study following the emergence of any laboratory abnormality or AE that', 'in the judgment of the Investigator compromises the ability to continue study-specific procedures', \"or is considered not to be in the subject's best interest.\", '14.5.', 'Records Retention', 'To enable evaluations and/or audits from regulatory authorities or BioCryst, the Investigator', 'agrees to keep records, including the identity of all participating subjects (sufficient information', 'to link records, CRFs, and medical/hospital records), all original signed ICFs, all original signed', 'assents (where applicable), all CRFs, and detailed records of study drug accountability and', 'treatment disposition. The records should be retained by the Investigator according to local', 'regulations or as specified in the Clinical Trial Agreement, whichever is longer.', 'If the Investigator relocates, retires, or for any reason withdraws from the study, the study', 'records may be transferred to an acceptable designee, such as another investigator, another', \"institution, or to BioCryst. The Investigator must obtain BioCryst's written permission before\", 'disposing of any records and must notify BioCryst before transferring any records to another', 'facility.', '101']\n\n###\n\n", "completion": "END"}